Stand Up To Cancer shared on LinkedIn:
“One of the things that makes pancreatic cancer so hard for doctors to treat is that tumors in the pancreas can be surrounded by a sort of protective barrier – a dense thicket of scar tissue, tangled blood vessels, and other things that block drugs from reaching the tumor.
But in a recent clinical trial, co-funded by Stand Up To Cancer, Cancer Research UK (CRUK), and The Lustgarten Foundation and led by Dr. Brian Wolpin from Dana-Farber Cancer Institute, showed that a vitamin D-like drug may make existing treatments for pancreatic cancer more effective. How? By weakening one of the most vital parts of this forcefield-like barrier.
The approach may offer a promising new way of combatting this deadly form of cancer. Learn more about this exciting research at SU2C.link/PancreaticStudy.”
You can also read:
- The Promise of Daraxonrasib: The Price of Progress in Pancreatic Cancer – Common Sense Oncology
- Nelson Dusetti Shares New Findings on the Methionine Cycle in Pancreatic Cancer
- Phase II HRS-4642 Plus Chemotherapy With or Without Adebrelimab in KRAS G12D-Mutant Pancreatic Cancer: Preliminary Results at ESMO 2026
